Sensus Healthcare Q1 2023 revenue $3.4M; net loss $1.9M; expects H2 profitability

Sensus Healthcare, Inc.

2023-Q1 EPS reported -$0.12 revenue$3,414,000

Revenue $3.4M vs $10.3M YoY; shipped 10 SRT systems vs 33.
Net loss $1.9M ($0.12 per share) vs net income $16.1M ($0.97 per share) in Q1 2022 (included $12.8M gain).
Gross margin fell to 47.1% from 68.9% due to lower volume and vendor cost increases.
Ended Q1 with $19.3M cash, no debt; expects >60 SRT shipments in 2023 and return to profitability in H2.
Management cites inflation impacting dermatologists' cash flow; higher selling & marketing expense.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sensus Healthcare, Inc. reported the three months ended March 31, 2023 results: revenue $3.4 million, net income Net loss was $1.9 million, or $0.12 per share.

Period: the three months ended March 31, 2023
Revenue: $3.4 million
Net income: Net loss was $1.9 million, or $0.12 per share
Result: reported results

Exact text from the filing

from the first quarter of 2023 and recent weeks include the following (all comparisons are with the first quarter of 2022, unless otherwise indicated): ● Revenues were $3.4 million, compared with $10.3 million, reflecting lower SRT unit sales ● Shipped 10 systems including three SRT systems to Asia and six domestic SRT systems, compared with 33 ● Net loss

View on SEC.gov

Browse all earnings releases →

Sensus Healthcare, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-035978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.